{"id":1199,"date":"2018-09-04T09:49:38","date_gmt":"2018-09-04T07:49:38","guid":{"rendered":"http:\/\/haavind.local\/en\/2018\/09\/04\/haavind-pharma-report-summer-2018\/"},"modified":"2022-07-21T12:51:19","modified_gmt":"2022-07-21T12:51:19","slug":"haavind-pharma-report-summer-2018","status":"publish","type":"post","link":"https:\/\/haavind.stage01.dekodes.no\/en\/haavind-pharma-report-summer-2018\/","title":{"rendered":"The Haavind Pharma Report Summer 2018"},"content":{"rendered":"\t
\n\t\t
\n\t\t\t
\n\t\t\t\t

The Haavind Pharma Report Summer 2018<\/h1>\n\n

We are proud to present the Summer edition of our biannual Pharma Report. The report looks at some of the legal developments during the first half of 2018 in the pharmaceutical sector in Norway.<\/p>\n\t\t\t\t\t\t\t\t\t\t\t\t\t

<\/div>\n\t\t\t\t\t
\n\t\t\t\t\t\t04 September, 2018 \u00b7 3 min. reading time<\/span>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\n
\n\t\t\t\tWritten by<\/span>\n\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t\t\t\t\n\t\t\t\t\t\t
\n\t\t\t\t\t\tH\u00e5kon Austdal<\/span>\n\t\t\t\t\t\tSpecialist Counsel<\/span>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/a>\n\t\t\t\t\t
\n\t\t\t\t\t\t\n\t\t\t\t\t\t
\n\t\t\t\t\t\tVebj\u00f8rn Krag Iversen<\/span>\n\t\t\t\t\t\tPartner<\/span>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/a><\/div>\n\t\t\t\t
\n\t\t\t\tTopics<\/span>\n\t\t\t\t
Healthcare and life science<\/span><\/div>\n\t\t\t\t<\/div>\n\t\t\t<\/div>\n\n

We are proud to present the Summer edition of our biannual Pharma Report. The report looks at some of the legal developments during the first half of 2018 in the pharmaceutical sector in Norway.<\/p>\n\n\n

The first half of 2018 has been an eventful six months for legal practitioners in the pharmaceutical sector. There have been important cases on regulatory affairs and intellectual property. We are therefore pleased to present a retrospective view on some of these legal developments.<\/p>\n\n\n\n

In this edition of our biannual report, you can read about AstraZeneca\u2019s challenge on the Norwegian Medicines Agency\u2019s decision to subject its blockbuster inhaler medicine to generic substitution. You can also read about several patent cases, including a case where we successfully represented a client who faced a preliminary injunction in connection with a patent on vaginal rings. Furthermore, you can also read about the Norwegian perspective on implementing the treatment for one of the world\u2019s most expensive drugs.<\/p>\n\n\n\n

Read the Summer edition of the Pharma Report here (e-book)<\/strong><\/a><\/p>\n\n\n\n

Download the Summer edition of the Pharma Report here (PDF)<\/strong><\/a><\/p>\n\n\n\n

Haavind\u2019s Health and Life Science team continuously and closely monitors developments in Norway relevant to the pharma sector. If you wish to discuss how your business can best meet the legal challenges of this innovative and highly regulated sector, you are always welcome to contact us.<\/p>\n\n\n\n

Would you like to receive our newsletters and future reports? Send us an email.<\/a><\/em><\/p>\n","protected":false},"excerpt":{"rendered":"

We are proud to present the Summer edition of our biannual Pharma Report. The report looks at some of the legal developments during the first half of 2018 in the pharmaceutical sector in Norway.<\/p>\n","protected":false},"author":0,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"sector":[7],"speciality":[],"acf":[],"yoast_head":"\nThe Haavind Pharma Report Summer 2018 - Haavind EN<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/haavind.stage01.dekodes.no\/en\/haavind-pharma-report-summer-2018\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"The Haavind Pharma Report Summer 2018\" \/>\n<meta property=\"og:description\" content=\"We are proud to present the Summer edition of our biannual Pharma Report. The report looks at some of the legal developments during the first half of 2018 in the pharmaceutical sector in Norway.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/haavind.stage01.dekodes.no\/en\/haavind-pharma-report-summer-2018\/\" \/>\n<meta property=\"og:site_name\" content=\"Haavind EN\" \/>\n<meta property=\"article:published_time\" content=\"2018-09-04T07:49:38+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-07-21T12:51:19+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/haavind.stage01.dekodes.no\/en\/haavind-pharma-report-summer-2018\/\",\"url\":\"https:\/\/haavind.stage01.dekodes.no\/en\/haavind-pharma-report-summer-2018\/\",\"name\":\"The Haavind Pharma Report Summer 2018 - Haavind EN\",\"isPartOf\":{\"@id\":\"https:\/\/haavind.stage01.dekodes.no\/en\/#website\"},\"datePublished\":\"2018-09-04T07:49:38+00:00\",\"dateModified\":\"2022-07-21T12:51:19+00:00\",\"author\":{\"@id\":\"\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/haavind.stage01.dekodes.no\/en\/haavind-pharma-report-summer-2018\/\"]}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/haavind.stage01.dekodes.no\/en\/#website\",\"url\":\"https:\/\/haavind.stage01.dekodes.no\/en\/\",\"name\":\"Haavind EN\",\"description\":\"-\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/haavind.stage01.dekodes.no\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"The Haavind Pharma Report Summer 2018 - Haavind EN","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/haavind.stage01.dekodes.no\/en\/haavind-pharma-report-summer-2018\/","og_locale":"en_US","og_type":"article","og_title":"The Haavind Pharma Report Summer 2018","og_description":"We are proud to present the Summer edition of our biannual Pharma Report. The report looks at some of the legal developments during the first half of 2018 in the pharmaceutical sector in Norway.","og_url":"https:\/\/haavind.stage01.dekodes.no\/en\/haavind-pharma-report-summer-2018\/","og_site_name":"Haavind EN","article_published_time":"2018-09-04T07:49:38+00:00","article_modified_time":"2022-07-21T12:51:19+00:00","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/haavind.stage01.dekodes.no\/en\/haavind-pharma-report-summer-2018\/","url":"https:\/\/haavind.stage01.dekodes.no\/en\/haavind-pharma-report-summer-2018\/","name":"The Haavind Pharma Report Summer 2018 - Haavind EN","isPartOf":{"@id":"https:\/\/haavind.stage01.dekodes.no\/en\/#website"},"datePublished":"2018-09-04T07:49:38+00:00","dateModified":"2022-07-21T12:51:19+00:00","author":{"@id":""},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/haavind.stage01.dekodes.no\/en\/haavind-pharma-report-summer-2018\/"]}]},{"@type":"WebSite","@id":"https:\/\/haavind.stage01.dekodes.no\/en\/#website","url":"https:\/\/haavind.stage01.dekodes.no\/en\/","name":"Haavind EN","description":"-","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/haavind.stage01.dekodes.no\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/haavind.stage01.dekodes.no\/en\/wp-json\/wp\/v2\/posts\/1199"}],"collection":[{"href":"https:\/\/haavind.stage01.dekodes.no\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/haavind.stage01.dekodes.no\/en\/wp-json\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/haavind.stage01.dekodes.no\/en\/wp-json\/wp\/v2\/comments?post=1199"}],"version-history":[{"count":1,"href":"https:\/\/haavind.stage01.dekodes.no\/en\/wp-json\/wp\/v2\/posts\/1199\/revisions"}],"predecessor-version":[{"id":3752,"href":"https:\/\/haavind.stage01.dekodes.no\/en\/wp-json\/wp\/v2\/posts\/1199\/revisions\/3752"}],"wp:attachment":[{"href":"https:\/\/haavind.stage01.dekodes.no\/en\/wp-json\/wp\/v2\/media?parent=1199"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/haavind.stage01.dekodes.no\/en\/wp-json\/wp\/v2\/categories?post=1199"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/haavind.stage01.dekodes.no\/en\/wp-json\/wp\/v2\/tags?post=1199"},{"taxonomy":"sector","embeddable":true,"href":"https:\/\/haavind.stage01.dekodes.no\/en\/wp-json\/wp\/v2\/sector?post=1199"},{"taxonomy":"speciality","embeddable":true,"href":"https:\/\/haavind.stage01.dekodes.no\/en\/wp-json\/wp\/v2\/speciality?post=1199"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}